The U.S. has documented 21 cases of anaphylaxis from over 1.8 million Pfizer-BioNTech vaccine doses administered between December 14 and 23. These reactions are rarer than initially feared and far less common than everyday risks, per CDC analysis.
Concerns about COVID-19 vaccine side effects are understandable, but early data from France's National Agency for the Safety of Medicines and Health Products (ANSM) offers reassurance on the Pfizer-BioNTech vaccine.
Clinical trials showed most side effects as mild to moderate, resolving quickly: injection-site pain, fatigue, headache, chills, joint pain, or low-grade fever.
After one week of vaccinations, ANSM Director General Christelle Ratignier-Carbonneil confirmed on Europe 1 (January 4): "No serious adverse effects reported in vaccinated individuals."
U.S. data aligns with this positivity. A CDC-led study reviewed 1,893,360 doses from December 14-23, 2020, identifying just 21 anaphylaxis cases post-first dose—a rate of about 11 per million doses, or 1 in 100,000.
By contrast, flu vaccines see 1.3 anaphylaxis cases per million, per Dr. Nancy Messonnier, CDC's National Center for Immunization and Respiratory Diseases Director. COVID-19 vaccine rates are roughly 10 times higher but "still extremely rare." She emphasized: "Vaccine benefits far outweigh risks."
17 of 21 cases involved prior allergies (to meds, foods, or insect bites); seven had previous anaphylaxis. All recovered, mostly with epinephrine.
Authorities advise 30-minute observation for those with allergy histories post-first dose, as most reactions occurred within 13 minutes.
